SLC7A6: A RNA Molecule Regulating Ion Channels and Neurotransmission

Target Name: SLC7A6OS

NCBI ID: G84138

SLC7A6OS

SLC7A6: A RNA Molecule Regulating Ion Channels and Neurotransmission

SLC7A6OS, also known as SLC7A6, is a member of the Sodium Chloride Transporter (SLC) family 7, which is responsible for transporting sodium ions (Na+) out of cells and into the cell membrane. It is an RNA molecule, which means it is made up of RNA strands.

SLC7A6 is a protein that is expressed in many different tissues and organs in the body. It is primarily located in the brain, where it is involved in the regulation of ion channels and neurotransmitter release. It is also expressed in the heart, kidneys, and pancreas, among other organs.

One of the key functions of SLC7A6 is its role in maintaining the resting membrane potential (RMP) of the brain. The RMP is the electrical potential difference between the most positive and most negative charges on the surface of each neuron. It is responsible for allowing neurons to communicate with each other and for generating the electrical signals that carry information throughout the brain.

SLC7A6 is also involved in the regulation of neurotransmitter release from the axon terminal of neurons. When a neuron is activated, the axon terminal releases a neurotransmitter, which can then transmit signals along the dendrites and the cell body of the neuron. SLC7A6 helps to regulate the amount of neurotransmitter that is released, which is critical for maintaining the integrity of the neural circuit.

SLC7A6 is a potential drug target because of its involvement in the regulation of ion channels and neurotransmitter release. Many neurotransmitters, including dopamine, serotonin, and kappa-opioid antagonists, have been shown to interact with SLC7A6. This suggests that SLC7A6 could be a useful target for the treatment of neurological and psychiatric disorders that are characterized by abnormal ion channel activity or neurotransmitter release.

In addition to its role in neurotransmission, SLC7A6 is also involved in the regulation of ion channels in the brain. It has been shown to interact with several different ion channels, including the Na+ channel. This suggests that SLC7A6 may be a useful target for the treatment of conditions that are characterized by changes in the activity of these channels, such as epilepsy and migraine.

SLC7A6 is also expressed in many different tissues and organs in the body, which makes it a potential biomarker for a variety of conditions. For example, it has been shown to be expressed in the brains of individuals with Alzheimer's disease, Parkinson's disease, and other neurological disorders. This suggests that SLC7A6 may be a useful biomarker for the diagnosis and treatment of these conditions.

In conclusion, SLC7A6 is a RNA molecule that is expressed in many different tissues and organs in the body. It is primarily located in the brain and is involved in the regulation of ion channels and neurotransmitter release. SLC7A6 is a potential drug target and biomarker for a variety of neurological and psychiatric disorders. Further research is needed to fully understand the role of SLC7A6 in the regulation of ion channels and neurotransmission, and to develop effective treatments for the disorders that are characterized by changes in these processes.

Protein Name: Solute Carrier Family 7 Member 6 Opposite Strand

Functions: Directs RNA polymerase II nuclear import

The "SLC7A6OS Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC7A6OS comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets